Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights November 29, 2023
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases November 27, 2023
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology November 7, 2023
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update August 29, 2023
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise August 25, 2023
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update May 25, 2023
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases May 23, 2023